IP Library › Granted Patent US 9,970,061
Granted Patent B2
US 9,970,061 · App. 14/369,618 · Granted May 15, 2018

Bioagent detection oligonucleotides

Inventors: David J. Ecker (Encinitas, CA); Steven A. Hofstadler (Vista, CA); Rangarajan Sampath (San Diego, CA); Lawrence B. Blyn (Mission Viejo, CA); Thomas A. Hall (Oceanside, CA); Mark W. Eshoo (San Diego, CA)
Assignee: IBIS BIOSCIENCES, INC.
C12Q1/689C12Q1/6853C12Q1/686C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,970,061
App. No.
14/369,618
Granted
May 15, 2018
Kind
B2
Abstract

The present invention compositions, methods and systems to identify, detect, and/or quantify bacterial DNA in the presence of contaminating non-bacterial DNA. In particular, the present invention provides oligonucleotides configured to detect a relatively small amount of bacterial DNA in the presence of an overwhelmingly large amount of contaminating human DNA.

Claims (15)

1. A method of detecting bacterial DNA in the presence of contaminating human DNA comprising:

a) contacting a sample comprising human genomic DNA, contaminants, and possibly bacterial DNA with an oligonucleotide wherein said oligonucleotide is 1 a sequence selected from SEQ ID NOs: 1-18;

b) allowing said oligonucleotide to hybridize to bacterial DNA, if bacterial DNA is present in said sample; and

c) detecting said bacterial DNA in the presence of contaminating human DNA, if bacterial DNA is present in said sample, based upon hybridization of said oligonucleotide to said bacterial DNA.

2. The method of claim 1 , further comprising quantifying said bacterial DNA.

3. The method of claim 1 , further comprising using SCODA to separate said bacterial DNA from said human genomic DNA.

4. The method of claim 1 , wherein said oligonucleotide comprises a label.

5. The method of claim 4 , wherein said label is a fluorescent label, a luminescent label, a chemiluminescent label, radioactive label, a quencher label, an interacting label, or a mass-tagged label.

6. The method of claim 1 , wherein said oligonucleotide is a capture oligonucleotide immobilized in a SCODA gel.

7. The method of claim 6 , wherein said bacterial DNA is eluted from said SCODA gel and amplified with a primer pair comprising a sequence selected from SEQ ID NOs: 1-18 prior to detection.

8. The method of claim 6 , wherein said bacterial DNA is amplified in said SCODA gel using in situ PCR methods with a primer pair comprising a sequence selected from SEQ ID NOs: 1-18 prior to detection, or prior to elution and detection.

9. The method of claim 8 , wherein an electrical field, a magnetic field, a flow field, or combination thereof promotes hybridization and disassociation of said bacterial DNA and said immobilized primers during rounds of said PCR.

10. The method of claim 8 , wherein said bacterial DNA is detected without elution from said SCODA gel wherein a sequence of said primer pair is detectably labeled.

11. The method of claim 7 , wherein said detection comprises next-generation sequencing detection.

12. The method of claim 7 , wherein said detection comprises quantifying said bacterial DNA.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2015
From: ECKER, DAVID J.; HOFSTADLER, STEVEN A.; SAMPATH, RANGARAJAN; BLYN, LAWRENCE B.; HALL, THOMAS A.; ESHOO, MARK W.
To: IBIS BIOSCIENCES, INC.
Reel/Frame 035942/0175 →
Continuity (2)
Provisional Application 61580499 · Dec 27, 2011
Related Publication 20150184231A1 · Jul 2, 2015